Endothelin-1 attenuates bradykinin-induced hypotension in rats

European Journal of Pharmacology

Volumn 397, Issue 2-3, 2000, Pages 367-371

  Tanus Santos, Jose E ^a   Gordo, Wladimir M ^a   Francisco DoPrado, Joaquim ^a   Sampaio, Rita C ^a   Moreno Jr , Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Blood pressure; Bradykinin; Enalapril; Endothelin 1; Losartan; Rat

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BRADYKININ; ENALAPRIL; ENDOTHELIN 1; LOSARTAN; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; HYPERTENSION; HYPOTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; BRADYKININ; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; ENDOTHELIN-1; HYPOTENSION; INJECTIONS, INTRAVENOUS; LOSARTAN; MALE; RATS; RATS, WISTAR;

EID: 0034595742     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00239-9     Document Type: Article

References (28)

1. Abernethy D.R., Laurie N., Andrawis N.S. Local angiotensin-converting enzyme inhibition blunts endothelin-1-induced increase in forearm vascular resistance. Clin. Pharm. Ther. 58:1995;328-334.
2. Battistini B., Chailler P., D'Orleans-Juste P., Briere N., Sirois P. Growth regulatory properties of endothelins. Peptides. 14:1993;385-399.
3. Benigni A., Remuzzi G. Endothelin antagonists. Lancet. 353:1999;133-138.
4. Carretero O.A., Miyazaki S., Scicli A.G. Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril. Hypertension. 3:1981;18-22.
5. Clavell A.L., Mattingly M.T., Stevens T.L., Nir A., Wright S., Aarhus L.L., Heublein D.M., Burnett J.C. Jr. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J. Clin. Invest. 97:1996;1286-1292.
6. Gray G.A., Webb D.J. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol. Ther. 72:1996;109-148.
7. Haynes W.G., Webb D.J. Contribuition of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 344:1994;852-854.
8. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 92:1995;357-363.
9. Hecker M., Blaukat A., Bara A.T., Müller-Esterl W., Busse R. ACE inhibitor potentiation of bradykinin-induced venoconstriction. Br. J. Pharmacol. 121:1997;1475-1481.
10. Kaito N., Onoue H., Abe T. Suppression of cerebral vasodilation with endothelin-1. Peptides. 16:1995;1127-1132.
11. Khono M., Yasunari K., Murakawa K., Yokokawa K., Horio T., Fukui T., Takeda T. Plasma immunoreactive endothelin in essential hypertension. Am. J. Med. 88:1990;614-618.
12. Levin E.R. Endothelins. N. Engl. J. Med. 333:1995;356-363.
13. Li J.S., Larivière R., Schiffrin E.I. Effect of a nonselective endothelin antagonist on vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension. 24:1994;183-188.
14. Linz W., Wohlfart P., Schölkens B.A., Malinski T., Wiemer G. Interactions among ACE, kinins and NO. Cardiovasc. Res. 43:1999;549-561.
15. 2 receptors and angiotensin I-converting enzyme in CHO cells. Circ. Res. 81:1997;848-856.
16. Moreno H. Jr., Nathan L.P., Costa S.K.P., Metze K., Antunes E., Zatz R., de Nucci G. Enalapril does not prevent the myocardial ischemia caused by chronic inhibition of nitric oxide synthesis. Eur. J. Pharmacol. 287:1995;93-96.
17. Panza J.A., Quyyumi A.A., Brush J.E., Epstein S.E. Abnormal endothelium-dependent relaxation in patients with essential hypertension. N. Engl. J. Med. 323:1990;22-27.
18. Rakugi H., Tabuchi Y., Nakamaru M., Nagano M., Higashimoroi K., Mikami H., Ogihara T., Suzuki N. Endothelin activates the vascular renin-angiotensin system in rat mesenteric arteries. Biochem. Int. 21:1990;867-872.
19. Regoli D., Allogho S.N., Rizzi A., Gobeil F.J. Bradykinin receptors and their antagonists. Eur. J. Pharmacol. 348:1998;1-10.
20. Rodrigo E., Maeso R., Muñoz-García R., Navarro-Cid J., Ruilope L.M., Cachofeiro V., Lahera V. Endothelial dysfunction in spontaneously rats: consequences of chronic treatment with losartan or captopril. J. Hypertens. 15:1997;613-618.
21. Rossi G.P., Sacchetto A., Cesari M., Pessina A.C. Interaction between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc. Res. 43:1999;300-307.
22. Rubanyi G.M., Polokoff M.A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46:1994;325-415.
23. Saito Y., Nakao K., Mukoyama M., Imura H. Increased plasma endothelin levels in patients with essential hypertension. N. Engl. J. Med. 322:1990;205.
24. Schiffrin E.L., Deng L.Y., Sventek P., Day R. Enhanced expression of endothelin-1 gene in endothelium of resistance arteries in severe human essential hypertension. J. Hypertens. 15:1997;57-63.
25. Vanhoutte P.M. Endothelial dysfunction and inhibition of converting enzyme. Eur. Heart J. 19(Suppl. J):1998;J7-J15.
26. Wong-Dusting H.K., La M., Rand M.J. Endothelin-1 enhances vasoconstrictor responses to sympathetic nerve stimulation and noradrenaline in the rabbit ear artery. Clin. Exp. Pharmacol. Physiol. 18:1991;131-136.
27. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yasaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
28. Yang Z., Richard V., Von Segesser L., Bauer E., Stulz P., Turina M., Luscher T.F. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation. 82:1990;188-195.